Document |
Document Title |
WO/2024/094208A1 |
The present invention relates to a series of cyano-substitute-containing heterocyclic derivatives and a preparation method therefor, and specifically relates to a compound represented by formula (IV), a stereoisomer thereof, and a pharma...
|
WO/2024/094575A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
WO/2024/097172A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
|
WO/2024/098066A1 |
Disclosed herein, in part, are novel exatecan derivatives with novel chemical linkers that include cathepsin B cleavable moieties and conjugated to targeting antibodies. In a preferred embodiment the antibody is an anti-TROP2, an anti-EG...
|
WO/2024/094016A1 |
The present invention provides a salt of a dioxane quinoline compound, a crystal form thereof, preparation methods therefor and uses thereof. Specifically, the present invention relates to N-(3-fluoro-4-((5-(3-morpholinopropoxy) -2,3-dih...
|
WO/2024/094156A1 |
Provided is a compound represented by formula (I), or a stereoisomer thereof, an optical isomer thereof, a solvate thereof, an isotope derivative thereof, or a pharmaceutically acceptable salt thereof. The compound can be used as a ligan...
|
WO/2024/088237A1 |
Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
|
WO/2024/090775A1 |
The present specification provides a heterocyclic compound, an organic light-emitting device comprising same, and a composition for an organic layer of an organic light-emitting device.
|
WO/2024/091983A1 |
The present invention relates to novel compounds and compositions thereof. The compositions are useful in the treatment of an epithelial or endothelial barrier dysfunction disorder in a subject.
|
WO/2024/091538A1 |
The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
|
WO/2024/089023A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
|
WO/2024/087977A1 |
The present invention relates to a phenylurea compound capable of targeting SHP2, and a preparation method therefor, the use thereof and a pharmaceutical composition thereof. The compound is as represented by formula (I). The present inv...
|
WO/2024/085699A1 |
The present disclosure provides a compound of a specific chemical structure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, which has excellent activity in te...
|
WO/2024/083773A1 |
The present invention relates to compounds, compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythemato...
|
WO/2024/086644A1 |
Described herein are compounds or conjugates of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain pr...
|
WO/2024/086111A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
WO/2024/086634A1 |
The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...
|
WO/2024/083237A1 |
The disclosure provides substituted heteroaryl bicyclic compounds as represented in Formula I and the use thereof, wherein, A1, A2, B1, B2, B3, ring Z, L, Cy1 and Cy2 are defined herein. The compounds of Formula I can be used to prevent ...
|
WO/2024/086744A2 |
Provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Formula (I) are as defined in the application. Such compounds can be useful as anti-cancer agents.
|
WO/2024/081372A1 |
The present invention relates to processes for the preparation of the compound of formula 1 from the intermediates the intermediates of formulae 8 to 10 in the presence of the cyclisation catalyst CuSO4 Compound 1 is the agent-linker con...
|
WO/2024/078569A1 |
The present invention relates to an aromatic amide derivative, a preparation method therefor, and a use of a pharmaceutical composition comprising same in medicine. Specifically, the present invention relates to an aromatic amide derivat...
|
WO/2024/081318A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
WO/2024/081904A1 |
This disclosure provides compounds of Formula (I), Formula (II), Formula (III), and pharmaceutically acceptable salts of any of the foregoing, that inhibit PI3Kα. These compounds are useful for treating diseases such as cancer in a subj...
|
WO/2024/081927A1 |
Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
|
WO/2024/078649A1 |
The invention relates to furopyridine compounds of formula (I) for use in the treatment of FLT3-related, DDR-related and MAP4K-related diseases.
|
WO/2024/078592A1 |
The present invention relates to a compound targeting fibroblast activation protein (FAP) as shown in formula (X) and a use thereof, and further relates to a pharmaceutical composition containing the compound and a use. The compound or t...
|
WO/2024/078449A1 |
The present disclosure relates to anticancer compounds, including, but not limited to, antibody-drug conjugates using the same, which compounds and ACDs thereof are suitable for the treatment of cancer.
|
WO/2024/074611A1 |
The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
|
WO/2024/077006A1 |
Described herein are radiotherapeutics that target tumor cells expressing the follicle-stimulating hormone receptor (FSHR) and their use in the treatment and/or diagnosis of cancer.
|
WO/2024/075051A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD an...
|
WO/2024/075070A2 |
The present invention relates to a compound represented by chemical formula 1 as an SOS1 inhibitor, optical isomers thereof, stereoisomers thereof, solvates thereof, isotopic variants thereof, tautomers thereof, or pharmaceutically accep...
|
WO/2024/073475A1 |
Described herein are compounds of Formula II or conjugates of Formula II' and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or degraders for certain p...
|
WO/2024/066984A1 |
Provided in the present invention is a tricyclic derivative, and the structure thereof is as shown in formula (I). In addition, further disclosed in the present invention are a pharmaceutically acceptable salt of the derivative, a stereo...
|
WO/2024/067445A1 |
Provided are a compound of formula (I) having inhibitory activity for protein arginine methyltransferase 5, and a method for synthesis and use of the compound.
|
WO/2024/073587A1 |
Compounds and methods for inhibiting Nrf2 by activating KEAP1.
|
WO/2024/069634A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of cancer in a subject in need thereof are also provided.
|
WO/2024/067811A1 |
Provided herein are compounds having formulas (I) or (VII) or pharmaceutically acceptable salts, tautomers, isotopologues, stereoisomers, or prodrugs thereof; ligand-drug conjugates and pharmaceutically acceptable salts or solvates there...
|
WO/2024/073426A1 |
Provided dihydroquinazolinone and azadihydroquinazolinone compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.
|
WO/2024/068517A1 |
The present invention relates to 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
|
WO/2024/069592A1 |
The present application discloses specific compounds of Formula (I) and their use in therapy, in particular, their use as Polymerase Theta (Polθ) inhibitors for the treatment of cancer. The application further discloses the use of a com...
|
WO/2024/069448A1 |
The present disclosure includes substituted 1-arylaminocarbonyl-1'-heteroaryl compounds, substituted 1-heteroarylaminocarbonyl-1'-heteroaryl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds...
|
WO/2024/062997A1 |
Compounds represented by the following general formula are useful as material for a photoelectric conversion element. Y is O or S, Ar1 and Ar2 are, e.g., aromatic hydrocarbon groups, and one of X1 to X4 is, e.g., a diarylamino group.
|
WO/2024/061048A1 |
Disclosed are a class of lycorine derivatives represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition thereof, and use thereof. The lycorine derivatives ...
|
WO/2024/061367A1 |
Disclosed are a novel compound, a pharmaceutical composition thereof, and use thereof. The novel compound is represented by formula (I), wherein the details of the definition of each substituent group are shown in the specification. The ...
|
WO/2024/064316A1 |
Described herein are compounds and conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 inhibitors or degraders).
|
WO/2024/063143A1 |
The present invention relates to a compound represented by formula (I) or (II) or a pharmaceutically acceptable salt thereof. Formula (I): [wherein: A1 is C(R1), etc.; R1 is a hydrogen atom, etc.; R8 is a hydrogen atom, etc.; B1 is CH,...
|
WO/2024/061357A1 |
The present invention relates to the field of pharmaceutical compounds, and relates to a harringtonine derivative, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. The harringtonine derivative and t...
|
WO/2024/064823A2 |
Provided herein, inter alia, are compositions comprising a staurosporine analog and methods for their use in cancer treatment.
|
WO/2024/064335A1 |
The disclosure provides naphthyl-substituted pyranopyrimidinones and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras activity and their use in the treatment of medical disorders, such as cancer.
|